Bone marrow aplasia - A rare complication of imatinib therapy in CML patients

20Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Imatinib mesylate therapy in CML patients is a generally well tolerated without any significant hematological adverse drug effects. However, complications like anemia and cytopenias have been described in literature. A very few case reports of bone marrow aplasia following imatinib therapy have been reported so far. We here report five patients of CML who developed bone marrow aplasia following imatinib therapy. © 2006 Wiley-Liss, Inc.

Author supplied keywords

Cite

CITATION STYLE

APA

Srinivas, U., Pillai, L. S., Kumar, R., Pati, H. P., & Saxena, R. (2007). Bone marrow aplasia - A rare complication of imatinib therapy in CML patients. American Journal of Hematology, 82(4), 314–316. https://doi.org/10.1002/ajh.20776

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free